CA Patent

CA2894170C — Lfa-1 inhibitor formulations

Assigned to Bausch and Lomb Ireland Ltd · Expires 2021-08-10 · 5y expired

What this patent protects

The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. …

USPTO Abstract

The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described.

Drugs covered by this patent

Patent Metadata

Patent number
CA2894170C
Jurisdiction
CA
Classification
—
Expires
2021-08-10
Drug substance claim
No
Drug product claim
No
Assignee
Bausch and Lomb Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.